Pirarubicin [72496-41-4]
P3568
Estimated Purity≥90%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NamePirarubicin [72496-41-4]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥90%
- Scientific DescriptionAnthracycline, DNA intercalator; topoisomerase II and DNA polymerase inhibitor.; THP
- Storage InstructionAmbient
- UNSPSC12352200
References
- Hiyama E, Ueda Y, Onitake Y, et al. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatr Surg Int. 2013 Oct;29(10):1071-5. PMID: 24026876. Kataoka K, Naomoto Y, Muro M, et al. Antitumor effect of pirarubicin (THP) against human colon cancer transplanted into nude mice and the mechanism of cell cycle progression. Gan To Kagaku Ryoho. 1992 Mar;19(3):367-71. PMID: 1543363. Hirano S, Agata N, Hara Y, et al. Pirarubicin-induced endothelium-dependent relaxation in rat isolated aorta. J Pharm Pharmacol. 1991 Dec;43(12):848-54. PMID: 1687584. Schott B, Robert J. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol. 1989 Jan 1;38(1):167-72. PMID: 2910297. Tanaka M, Yoshida S, Kimura K. Mechanism of inhibition of DNA polymerases by 4'-epiadriamycin and 4'-O-tetrahydropyranyladriamycin. Gann. 1983 Dec;74(6):829-36. PMID: 6365674.